Kingsberg S, Clayton A, Clayton D, et al. - Researchers investigated whether bremelanotide is a safe and efficacious treatment option for premenopausal women with hypoactive sexual desire disorder. In two identical phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trials (RECONNECT), bremelanotide 1.75 mg was administered subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder. Randomization of patients 1:1 to 24 weeks of treatment with bremelanotide or placebo was done. Findings from both studies illustrate the efficacy of bremelanotide in improving sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder. The drug had a favorable safety profile with most treatment-emergent adverse events related to tolerability; the majority of these were mild or moderate in intensity.